PHARMACIST

The following questions are similar to what you may be asked during your interview. Please read through the following questions and think about how you would answer them. Let us know if there is any information we can give you to assist in the answers.

1. How are investigational drugs and devices stored? Temperature control? Access control?
2. Is there separate dedicated space for investigational drugs that is separate from the non-investigational drugs?
3. Is there any differentiation between investigational drugs and regular clinical care drugs?
4. How do inpatients and outpatients receive investigational drugs and devices?
5. Is the pharmacy involved in preparation of investigational materials? Reconstitution? Preparation of placebos?
6. Do you have a mechanism to ensure that all clinical trials requesting for the pharmacy services have IRB approval?
7. Have you ever had an occurrence involving emergency use of an investigational drug? If so, how did the investigational pharmacy ensure that informed consent had been obtained since there is no IRB-approved consent form?
8. How do you ensure that only clinical trial participants receive investigational materials?
9. After the end of the study, how are investigational materials disposed?
10. How do you ensure that there is sufficient documentation to support the interactions or interventions done with the subject in the IRB-approved protocol?
11. What is the time lapse of pharmacy notification when the IRB suspends or terminates a study, and how is it communicated?
12. What is the investigational pharmacist’s role in IND verification/validation/determination whether one should exist?
13. If your pharmacy is responsible for security of some of the investigational devices, how is that addressed by your investigational pharmacist?
14. What is the system in place to ensure that the correct person is prescribing the investigational drug and that the patient is actually a subject in the study?
15. Does MMC have any studies in which the investigator holds the IND and serves as the sponsor? If so, what, if any, is the investigational pharmacist’s role in education or assisting the sponsor-investigator fulfill their drug accountability requirements?
16. What type of quality assurance activities is the investigational pharmacist directly involved in, and what other entities within MMC receive reports of those activities (both quality assurance and quality improvement)?